Phase 4Recruiting
LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering (SOLVE-LDL-C)
Study of Optimal LDL-C Value Enhancement With Inclisiran in Patients With Multiple Comorbidities in Which There Are Drug-Drug Interactions Limiting LDL-C Lowering
- Sponsor
- University of California, San Diego (Academic or other)
- Enrollment
- 100 planned
- Conditions
- Drug Interactions; Primary Prevention; Cardiometabolic Syndrome; LDL-Cholersterol Lowering; Polypharmacy
- Interventions
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Ages
- adults, older adults
- Registry
- NCT06865885
Full record on ClinicalTrials.gov
From the registry
Polypharmacy and drug-drug interactions often limit statin optimization, including in a population of patients prescribed cytochrome P3A4 inhibitors such as, immunosuppressive agents, protease inhibitors, and antifungals. These patients frequently have autoimmune conditions or rheumatologic disorders that require complex drug regimens and are often on low-dose statin therapy or no statin at all, resulting in suboptimal LDL levels despite increased cardiovascular (CV) risk. There is an unmet clinical need to improve LDL levels in this vulnerable patient population, which faces increased CV risk due to underlying conditions that also contribute to polypharmacy and multiple drug-drug interactions. This study is a randomized, open-label trial evaluating subcutaneous inclisiran plus standard of care for LDL-C lowering in high-risk primary prevention patients with multiple comorbidities (e.g., type II diabetes, liver disease, chronic kidney disease, autoimmune disease, solid-organ transplant, etc.) who are taking five or more medications in which drug-drug interactions may prevent…
Primary outcomes
- Change of LDL-Cholesterol
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered